vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and NAPCO SECURITY TECHNOLOGIES, INC (NSSC). Click either name above to swap in a different company.

NAPCO SECURITY TECHNOLOGIES, INC is the larger business by last-quarter revenue ($48.2M vs $37.2M, roughly 1.3× GYRE THERAPEUTICS, INC.). NAPCO SECURITY TECHNOLOGIES, INC runs the higher net margin — 28.0% vs -3.7%, a 31.7% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 12.2%). NAPCO SECURITY TECHNOLOGIES, INC produced more free cash flow last quarter ($14.5M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -1.1%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

Napco Security Technologies, Inc. was set up in 1969 and now is based in Amityville, New York. The company focuses on security products, such as electronic locking devices, alarm systems, and building access control systems. The company was formerly known as Napco Security Systems, Inc.

GYRE vs NSSC — Head-to-Head

Bigger by revenue
NSSC
NSSC
1.3× larger
NSSC
$48.2M
$37.2M
GYRE
Growing faster (revenue YoY)
GYRE
GYRE
+21.2% gap
GYRE
33.4%
12.2%
NSSC
Higher net margin
NSSC
NSSC
31.7% more per $
NSSC
28.0%
-3.7%
GYRE
More free cash flow
NSSC
NSSC
$20.3M more FCF
NSSC
$14.5M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
-1.1%
NSSC

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
GYRE
GYRE
NSSC
NSSC
Revenue
$37.2M
$48.2M
Net Profit
$-1.4M
$13.5M
Gross Margin
95.3%
58.6%
Operating Margin
0.3%
30.6%
Net Margin
-3.7%
28.0%
Revenue YoY
33.4%
12.2%
Net Profit YoY
-340.1%
29.0%
EPS (diluted)
$-0.01
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
NSSC
NSSC
Q4 25
$37.2M
$48.2M
Q3 25
$30.6M
$49.2M
Q2 25
$26.8M
$50.7M
Q1 25
$22.1M
$44.0M
Q4 24
$27.9M
$42.9M
Q3 24
$25.5M
$44.0M
Q2 24
$25.2M
$50.3M
Q1 24
$27.2M
$49.3M
Net Profit
GYRE
GYRE
NSSC
NSSC
Q4 25
$-1.4M
$13.5M
Q3 25
$5.9M
$12.2M
Q2 25
$1.6M
$11.6M
Q1 25
$3.7M
$10.1M
Q4 24
$569.0K
$10.5M
Q3 24
$2.9M
$11.2M
Q2 24
$4.5M
$13.5M
Q1 24
$9.9M
$13.2M
Gross Margin
GYRE
GYRE
NSSC
NSSC
Q4 25
95.3%
58.6%
Q3 25
94.7%
56.6%
Q2 25
95.7%
52.8%
Q1 25
95.9%
57.2%
Q4 24
95.8%
57.0%
Q3 24
96.2%
55.9%
Q2 24
96.9%
55.3%
Q1 24
96.4%
53.8%
Operating Margin
GYRE
GYRE
NSSC
NSSC
Q4 25
0.3%
30.6%
Q3 25
22.7%
27.7%
Q2 25
8.1%
23.8%
Q1 25
10.3%
25.4%
Q4 24
2.4%
26.0%
Q3 24
16.6%
26.9%
Q2 24
12.7%
27.7%
Q1 24
29.7%
29.4%
Net Margin
GYRE
GYRE
NSSC
NSSC
Q4 25
-3.7%
28.0%
Q3 25
19.4%
24.7%
Q2 25
5.9%
22.9%
Q1 25
16.9%
23.0%
Q4 24
2.0%
24.4%
Q3 24
11.2%
25.4%
Q2 24
18.0%
26.9%
Q1 24
36.6%
26.8%
EPS (diluted)
GYRE
GYRE
NSSC
NSSC
Q4 25
$-0.01
$0.38
Q3 25
$0.03
$0.34
Q2 25
$0.00
$0.33
Q1 25
$0.00
$0.28
Q4 24
$0.00
$0.28
Q3 24
$0.01
$0.30
Q2 24
$0.01
$0.36
Q1 24
$0.03
$0.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
NSSC
NSSC
Cash + ST InvestmentsLiquidity on hand
$52.4M
$115.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$106.0M
$184.8M
Total Assets
$166.1M
$212.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
NSSC
NSSC
Q4 25
$52.4M
$115.4M
Q3 25
$60.0M
$105.8M
Q2 25
$54.4M
$99.2M
Q1 25
$29.9M
$89.3M
Q4 24
$26.7M
$99.2M
Q3 24
$25.1M
$91.3M
Q2 24
$25.1M
$70.7M
Q1 24
$37.4M
$60.9M
Stockholders' Equity
GYRE
GYRE
NSSC
NSSC
Q4 25
$106.0M
$184.8M
Q3 25
$101.9M
$176.1M
Q2 25
$92.0M
$168.6M
Q1 25
$68.1M
$161.5M
Q4 24
$63.3M
$174.2M
Q3 24
$63.2M
$178.6M
Q2 24
$60.4M
$178.9M
Q1 24
$56.6M
$168.2M
Total Assets
GYRE
GYRE
NSSC
NSSC
Q4 25
$166.1M
$212.8M
Q3 25
$159.4M
$206.0M
Q2 25
$152.6M
$198.1M
Q1 25
$129.8M
$190.9M
Q4 24
$125.4M
$202.7M
Q3 24
$125.2M
$209.9M
Q2 24
$120.9M
$207.8M
Q1 24
$122.0M
$194.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
NSSC
NSSC
Operating Cash FlowLast quarter
$-5.6M
$15.1M
Free Cash FlowOCF − Capex
$-5.8M
$14.5M
FCF MarginFCF / Revenue
-15.5%
30.1%
Capex IntensityCapex / Revenue
0.4%
1.2%
Cash ConversionOCF / Net Profit
1.12×
TTM Free Cash FlowTrailing 4 quarters
$-180.0K
$53.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
NSSC
NSSC
Q4 25
$-5.6M
$15.1M
Q3 25
$4.7M
$11.6M
Q2 25
$2.1M
$14.6M
Q1 25
$-129.0K
$13.4M
Q4 24
$-2.8M
$13.5M
Q3 24
$1.7M
$12.0M
Q2 24
$-5.5M
$14.3M
Q1 24
$2.9M
$12.3M
Free Cash Flow
GYRE
GYRE
NSSC
NSSC
Q4 25
$-5.8M
$14.5M
Q3 25
$4.0M
$11.4M
Q2 25
$1.8M
$14.4M
Q1 25
$-251.0K
$13.3M
Q4 24
$-2.8M
$12.4M
Q3 24
$1.0M
$11.3M
Q2 24
$-6.9M
$13.8M
Q1 24
$2.7M
$12.0M
FCF Margin
GYRE
GYRE
NSSC
NSSC
Q4 25
-15.5%
30.1%
Q3 25
13.1%
23.3%
Q2 25
6.8%
28.4%
Q1 25
-1.1%
30.3%
Q4 24
-10.1%
28.8%
Q3 24
4.1%
25.8%
Q2 24
-27.5%
27.4%
Q1 24
9.8%
24.3%
Capex Intensity
GYRE
GYRE
NSSC
NSSC
Q4 25
0.4%
1.2%
Q3 25
2.2%
0.4%
Q2 25
1.0%
0.5%
Q1 25
0.6%
0.1%
Q4 24
0.2%
2.6%
Q3 24
2.7%
1.5%
Q2 24
5.8%
1.1%
Q1 24
0.9%
0.7%
Cash Conversion
GYRE
GYRE
NSSC
NSSC
Q4 25
1.12×
Q3 25
0.79×
0.96×
Q2 25
1.32×
1.26×
Q1 25
-0.03×
1.32×
Q4 24
-4.85×
1.29×
Q3 24
0.60×
1.08×
Q2 24
-1.21×
1.06×
Q1 24
0.29×
0.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons